|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 结直肠癌患者血清TK1、sICAM-1、miR-210、CEA的检测及分析显示文摘目的探讨结直肠癌患者血清胸苷激酶1(TK1)、可溶性细胞间黏附分子-1(sICAM-1)、miR-210、癌胚抗原(CEA)的表达及意义。方法选取2015-2017年在该院就诊的结直肠癌患者200例作为观察组,健康体检者50例作为对照组。检测患者治疗前和治疗后2个月血清TK1、sICAM-1、miR-210、CEA水平,分析各指标的变化趋势。分析结直肠癌患者肿瘤部位、分化程度、临床分期、患病情况、淋巴结有无转移与miR-210水平间的关系。结果观察组sICAM-1、CEA、sTK1、miR-210的水平明显高于对照组(P<0.05),miR-210的水平与临床分期及有无淋巴结转移有关(P<0.05)。血清TK1、sICAM-1、miR-210、CEA四项联合检测对结直肠癌诊断的灵敏度、特异度、阳性预测值、阴性预测值和准确度均比单项检测的高,也高于TK1、miR-210、CEA三项联合检测。四项联合检测的灵敏度为75.70%,特异度为86.00%,阳性预测值为82.00%,阴性预测值为88.00%,准确度为92.40%。结论血清TK1、sICAM-1、miR-210、CEA联合检测可能对于结直肠癌早期诊断具有一定价值,能提高诊断结直肠癌的灵敏度和特异度。 | 刘懿 赵四海 | 2018 | 国际检验医学杂志2018，39，9： | 8 |
| 2 | Prognostic factors and therapeutic effects of different treatment modalities for colorectal cancer liver metastases显示文摘BACKGROUND Colorectal cancer(CRC)is one of the most common malignant tumors in China,and the liver is the most common metastatic site in patients with advanced CRC.Hepatectomy is the gold standard treatment for colorectal liver metastases.For patients who cannot undergo radical resection of liver metastases for various reasons,ablation therapy,interventional therapy,and systemic chemotherapy can be used to improve their quality of life and prolong their survival time.AIM To explore the prognostic factors and treatments of liver metastases of CRC.METHODS A retrospective analysis was conducted on 87 patients with liver metastases from CRC treated at the Liaoning Cancer Hospital and Institute between January 2005 and March 2011.According to different treatments,the patients were divided into the following four groups:Surgical resection group(36 patients);ablation group(23 patients);intervention group(15 patients);and drug group(13 patients).The clinicopathological data and postoperative survival of the four groups were analyzed.The Kaplan-Meier method was used for survival analysis,and the Cox proportional hazards regression model was used for multivariate analysis.RESULTS The median survival time of the 87 patients was 38.747±3.062 mo,and the 1-and 3-year survival rates were 87.5%and 53.1%,respectively.The Cox proportional hazards model showed that the following factors were independent factors affecting prognosis:The degree of tumor differentiation,the number of metastases,the size of metastases,and whether the metastases are close to great vessels.The results of treatment factor analysis showed that the effect of surgical treatment was better than that of drugs,intervention,or ablation alone,and the median survival time was 48.83±4.36 mo.The drug group had the worst prognosis,with a median survival time of only 13.5±0.7 mo(P<0.05).For patients with liver metastases of CRC near the great vessels,the median survival time(27.3 mo)of patients undergoing surgical resection was better than that of patients using other treatments(20.6 mo)(P<0.05).CONCLUSION Patients with a low degree of primary tumor differentiation,multiple liver metastases(number of tumors>4),and maximum diameter of liver metastases>5 cm have a poor prognosis.Among drug therapy,intervention,ablation,and surgical treatment options,surgical treatment is the first choice for liver metastases.When liver metastases are close to great vessels,surgical treatment is significantly better than drug therapy,intervention,and ablation alone. | Zuo-Hong Ma Yong-Peng Wang Wen-Heng Zheng Ji Ma Xue Bai Yong Zhang Yuan-He Wang Da Chi Xi-Bo Fu Xiang-Dong Hua | 2020 | World Journal of Gastrointestinal Oncology2020，12，10： | 7 |
| 3 | 腹腔镜直肠癌根治术后异时性肝转移的危险因素及预后分析显示文摘目的分析腹腔镜直肠癌根治术后发生异时性肝转移的危险因素,探讨影响肝转移患者预后的因素。方法分析2010~2016年我院327例行腹腔镜直肠癌根治术患者的临床资料、预后情况等资料,采用单因素和Cox比例风险回归模型等分析影响腹腔镜直肠癌根治术后异时性肝转移的危险因素及生存的相关因素。结果 327例患者中位随访时间为31个月(7~46个月)。TNM分期Ⅰ期32例,Ⅱ期98例,Ⅲ期197例。手术后半年以上共发生81例(24.7%)异时性肝转移。患者术后随访至诊断为肝转移的中位时间为16个月。肝转移的患者生存时间为(18±7)个月,3年累积生存率为22.6%;未发生肝转移的患者生存时间为(36±8)个月,3年累积生存率为75.3%;两者的生存情况比较,差异有统计学意义(χ~2=18.314,P<0.05)。多因素分析结果显示:淋巴结转移是影响腹腔镜直肠癌根治术后异时性肝转移的独立危险因素(OR=3.271,P<0.05)。术前CEA水平>5μg/L和是否切除肝转移瘤是影响肝转移患者预后不良的独立危险因素(P<0.05)。结论腹腔镜直肠癌根治术后是否发生肝脏转移是影响患者生存的重要因素,淋巴结转移是发生术后异时性肝转移的高危因素,术前CEA异常升高和是否再次手术切除肝转移病灶是影响异时性肝转移患者预后的独立相关因素。 | 但杰 王健 王永洪 朱明杰 彭忠 蒋鸿元 陈雷 | 2018 | 实用医院临床杂志2018，15，2： | 6 |
| 4 | MRI优化组合序列对乳腺疾病的应用价值显示文摘目的探析MRI优化组合序列对乳腺疾病的应用价值。方法随机选取该院在2016年1月—2018年1月期间收治的86例乳腺疾病患者,将患者分为对照组43例和治疗组43例,其中对照组行常规方式进行诊断,治疗组采用MRI成像优化组合序列方式进行诊断,比较两组患者的乳腺疾病检出率、准确率、敏感度。结果该研究共计86例乳腺疾病患者,其中对照组43例行常规方式诊断患者乳腺疾病,检出率为72.09%(31/43),准确率为76.74%(33/43),敏感度为74.42%(32/43);治疗组43例采用MRI优化组合序列方式诊断患者乳腺疾病,疾病检出率为97.67%(42/43),准确率为95.35%(41/43),敏感度为93.02%(40/43)。治疗组患者乳腺疾病检出率、准确率、敏感度均明显高于对照组,差异有统计学意义(χ2=12.358,11.027,9.162,P<0.05)。结论 MRI优化组合序列对乳腺疾病的应用价值较高,提高乳腺疾病诊断准确率,减少患者创伤,增强患者安全感,值得临床推广应用。 | 顾勇坚 梅莉 王开香 周鸿雁 | 2019 | 中外医疗2019，38，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员